Original Article

The Effectiveness of Bundle Applications in the Prevention of Central Line-associated Bloodstream Infections: Nine Years of Observation

Bahar Madran
×Affiliations
  • Infection Control Department, American Hospital, İstanbul, Turkey
,
Şiran Keske
×Affiliations
  • Koç University İş Bank Research Center for Infectious Diseases, Istanbul, Turkey
  • Department of Infectious Diseases and Clinical Microbiology, Koç University, School of Medicine, İstanbul, Turkey
,
Veli Oğuzalp Bakır
×Affiliations
  • Department of Industrial Engineering and Operations Management, Koç University, School of Sciences and Engineering, İstanbul, Turkey
,
Önder Ergönül
×Affiliations
  • Koç University İş Bank Research Center for Infectious Diseases, İstanbul, Turkey
  • Department of Infectious Diseases and Clinical Microbiology, Koç University, School of Medicine, İstanbul, Turkey

Abstract

Objective: This study aimed to assess the effectiveness of chlorhexidine-impregnated dressing in a bundle of interventions to reduce the rate of central line-associated bloodstream infections (CLABSIs).

Materials and Methods: We performed a bundle of interventions to reduce the CLABSIs from 2012. As one bundle component, we started using the chlorhexidine impregnated catheter dressing. We used a document describing applying central venous catheters for the practicing physicians and nurses, and we organized several educational meetings. An interrupted time-series analysis was performed.

Results: Seventy-six CLABSI events were detected in total between January 1, 2011, and December 31, 2019. Twenty-six cases were detected in the pre-intervention period (January 1, 2011, to December 31, 2011), and 50 patients were seen in the post-intervention term (January 1, 2012, to December 31, 2019). The annual CLABSI rate was 2.60/1000 catheter days in the pre-intervention period and 0.46/1000 catheter days (p=0.0328) in the post-intervention period. The CLABSI rate among hematology-oncology inpatients decreased from 3.39 to 0.71 (p=0.0101) in the same term.

Conclusion: By using bundle form including chlorhexidine impregnated dressing, the rate of CLABSIs decreased significantly. This effect has been observed consistently for nine years, and the clinical pathway use has become the standard care protocol.

Keywords: Chlorhexidine, bundle, central line-associated bloodstream infections.

Highlights

  • To reduce the rate of catheter-related bloodstream infections, a locally adapted bundle should be used.
  • The bundles including chlorhexidine impregnated dressing are practical in decreasing catheter-related bloodstream infections.
  • The use of chlorhexidine impregnated dressing is effective to decrease catheter-related bloodstream infections among hematology-oncology patients.

Introduction

Central line-associated bloodstream infections (CLABSIs) are the most common cause of mortality among healthcare-associated infections (HAIs). In the United States of America (USA), one-third of the fatalities among HAIs are caused by CLABSI; as many as 28,000 patients die from CLABSI annually in healthcare facilities (1, 2). Furthermore, the CLABSI rate was reported as 5.3 per 1000 catheter days in the United States (U.S.), whereas it was between 0.1 and 10.8 per 1000 catheter days in Turkey (3). Notably, the patients in intensive care units (ICUs) have an increased risk for CLABSI because 48% of ICU patients have indwelling central venous catheters, accounting for 15 million main line days per year in ICUs of the U.S. (4).

The prevention of CLABSIs could reduce the adverse outcomes, such as the excessive risk of mortality, long-term hospitalization, and medical costs. The CLABSIs were reported among the most costly HAIs at 45,814 USD; moreover, the annual fee of CLABSIs is more than 1 billion USD. In addition, the CLABSI might increase the duration of hospitalization by more than 12 days (5-8).

The Centers for Disease Control and Prevention (CDC) published a guideline for preventing intravascular catheter-related infections in May 2011. That guideline highlighted the significance of hand hygiene and aseptic techniques, maximal sterile barrier precautions during central catheter indwelling procedure, the use of bundles, avoiding the femoral vein, the education of healthcare workers (HCW) to implement central venous catheter (9). We implemented a bundle based on that guideline from the year 2012. The beneficial effects of using chlorhexidine gluconate (CHG) impregnated dressing were reported for reducing the CLABSI rate (10); however, there are controversial reports from real-life experiences (11). Therefore, this study aimed to describe the effect of our interventions, including chlorhexidine on skin preparation and dressing, to permanently decrease the rate of CLABSI.

Material and Method

The study was conducted in a tertiary care hospital in Istanbul with a 300-bed capacity between January 1, 2011, and December 31, 2019. The study population consists of all inpatients, including the ICU and hematology-oncology departments. All the cases with HAIs were classified based on CDC guidelines that were updated at that time and were evaluated by the same infection control team members.

A CLABSI was defined as a laboratory-confirmed bloodstream infection that develops more than 48 hours after a central line placement at the time of the event and is not secondary to another infection site (12-14).

The rate of CLABSI:    

We performed interventions to decrease the CLABSI rates based on the CDC guidelines (9, 12, 13). A central venous catheter (CVC) bundle was prepared and applied for all cases in whom CVC was inserted. The bundle includes insertion site, time and type of the catheter, the HCW who implemented the catheter, hand hygiene compliance during the procedure, compliance to the asepsis and anti-sepsis rules, the use of ultrasonography, the implementation and follow up of the dressing material. The dressing material was altered from classical gauze bandage to Tegaderm™ CHG1659 (3M™, Minnesota, U.S.) impregnated dressing (9). If required, the dressing of the catheter insertion site was changed by the HCW. However, if there was no visible problem, the dressing remained until seven days. Additionally, the insertion site for the CVC was suggested to be subclavian or jugular veins in the bundle. We arranged periodic educational meetings about the new bundle steps for healthcare workers. The same CHG product was used throughout the bundle.

Koç University Ethical Committee for Research Studies approved the study with the decision number of 2019.144.IRB1.018.

Statistical Analysis

Interrupted time series analysis for nine years was performed with the unit of time as one year. For test statistics, the R programming language (R Foundation for Statistical Computing) was used. Statistical significance for the slope of the line was set as p<0.05.

Results

Figure 1.
a. The CLABSI rates per 1000 catheter days among all inpatients during the study period,
b. The CLABSI rates per 1000 catheter days among hematology-oncology inpatients during the study period,
c. The CHG impregnated dressing use days in 1000 bed days during the study period,
d. The CLABSI rates per 1000 catheter days during the study period.

Table 1. Characteristics of the inpatients and the catheter use.

Table 2. The bacteria detected in catheter-line associated bloodstream infections.

Table 3. General infection control measures that potentially decrease CLABSI rates in the post-intervention period.

In total, 149,023 inpatients with 506,291 bed days between 2011-2019 were included in the study. The CLABSI rate decreased from 2.6 in 2011 to 0.46 per 1000 catheter days (p=0.032 Table 1, Figure 1) in the post-intervention period, despite the increase in the number of CVC use from 145 to 229 per 1000 inpatient days (p<0.001, Table 1), the number of CHG impregnated dressing use from 65 to 109 per 1000 inpatients days (p=0.026, Table 1, Figure 1).

The detected agents for CLABSI infections were Staphylococcus sp. (32%), E. coli (21%), Candida sp. (13%), K. pneumoniae (12%), P. aeruginosa (9%), Enterobacter sp. (8), A. baumannii (5%) (Table 2). General infection control measures that potentially contributed to the decrease of CLABSI rates were described in Table 3. Among general infection control measures, the hand hygiene compliance rate was 76% in 2011 and increased to 81% in 2015 and 85% in 2019.

Discussion

The CLABSI is one of the most critical HAIs with high morbidity, mortality, and healthcare costs.  This study demonstrated the decline in CLABSI rate by using CHG impregnated dressing and implementing a bundle of infection control practices. Despite our hospital’s lower baseline CLABSI rate than other hospitals in Turkey, a lower level of the CLABSI rate was sustained over nine years (Figure 1). The rate of CLABSI per 1000 catheter-days was 2.6 in the pre-intervention period and decreased to 0.46 in the post-intervention period (p=0.032).

In our study, the leading causative agent for CLABSI was Staphylococcus sp. However, 55% of the agents were Gram-negative microorganisms (Table 2). The most common pathogens in CLABSI are Gram-negative bacteria (15) in our region. The increase in the CLABSI caused by multidrug-resistant (MDR) Gram-negative microorganisms led to increased mortality. In a recent study from Turkey, two folds increase in mortality was reported among the patients with CLABSI (15). Therefore, the infection control precautions have a high impact on the prevention of transmission of MDR pathogens. In our study period, the case fatality rate was 0.01 (15/149,023 per 100 cases, Table 1).

The patients from ICU were commonly included in published studies (16-18); however, in our study, besides the ICU, we had the inpatients from hematology-oncology units and pediatrics. The total number of patients and admission to hematology-oncology units increased (p=0.010 and p≤0.001). Accordingly, the rate of CVC use (p=0.031) and CHG impregnated dressing days increased (p=0.026). However, the incidence of CLABSI decreased throughout the study period.

Including a very high number of inpatients and having nine years of study were the most vital points of our study compared to the previous similar reports (17-19). The rate of fulfilling the bundle form was 100%, which shows higher rates of accommodation if compared with the other studies (19). The higher cost of the catheter which might decrease its wide use is one of the main problems for resource-limited countries. The cost-effectiveness studies for the use of CHG in resource-limited countries might be beneficial.

In our hospital, the CLABSI rate was low at the beginning of the study which might be explained by several reasons including general infection control rules, high level of hand hygiene compliance, single-patient rooms, periodic hospital-wide educational activities. Despite the low CLABSI rates at the beginning of the study, the CLABSI continued to decrease during the study period.

Our study has nine years of data with high sample size. Each infection case was followed up very closely by the same dedicated infection control committee members. Besides these strengths, our study has some limitations. The study was conducted in a single facility. Moreover, the lack of standardized CLABSI definition imposed a challenge when comparing CLABSI surveillance data. We used timely CDC guidelines updated at that time. The improvement over time, which could be called maturity bias, could affect the outcome positively.

Conclusions

At the end of nine years of observation, chlorhexidine impregnated dressing as one of the components of a bundle was very useful in preventing CLABSI.

Ethical Approval: Koç University Ethical Committee for Research Studies approved the study with the decision number of 2019.144.IRB1.018.

Informed Consent: N.A

Peer-review: Externally peer-reviewed

Author Contributions: Concept – B.M., Ö.E.; Design – B.M., Ş.K., V.O.B.; Supervision –  Ö.E.; Data Collection and/or Processing – B.M., Ş.K., V.O.B.; Analysis and/or Interpretation – Ş.K., Ö.E., V.O.B.; Literature Review – B.M., Ş.K.; Writer – B.M., V.O.B.; Critical Reviews – Ö.E., Ş.K.

Conflict of Interest: The authors declare no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Acknowledgement: We are thankful to all healthcare workers for their effort to participate in the study. Additionally, we are grateful to hospital management for their support.

Show References

References

  1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-208. [CrossRef]
  2. Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol. 2020;41(1):1-18. [CrossRef]
  3. Hekimoğlu CH, Batır E, Yıldırım GE. The national short report of health care-associated infections in Turkey Ministry of Health Turkey; 2019 [Internet]. (cited February 25, 2020). Available from: https://hsgm.saglik.gov.tr/depo/birimler/Bulasici-hastaliklar-db/hastaliklar/SHIE/Raporlar/UHESA_Ozet_Raporu_2018.pdf
  4. Eliminating CLABSI, a national patient safety imperative: final report [Internet].  Agency for Healthcare Research and Quality (AHRQ). (updated January, 2013; cited February 27, 2020). Available from: https://www.ahrq.gov/hai/cusp/clabsi-final/index.html
  5. Glied S, Cohen B, Liu J, Neidell M, Larson E. Trends in mortality, length of stay, and hospital charges associated with health care-associated infections, 2006-2012. Am J Infect Control. 2016;44(9):983-9. [CrossRef]
  6. Stevens V, Geiger K, Concannon C, Nelson RE, Brown J, Dumyati G. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. Clin Microbiol Infect. 2014;20(5):O318-24. [CrossRef]
  7. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32(2):101-14. [CrossRef]
  8. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-46. [CrossRef]
  9. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162-93. [CrossRef]
  10. Safdar N, O’Horo JC, Ghufran A, Bearden A, Didier ME, Chateau D, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis. Crit Care Med. 2014;42(7):1703-13. [CrossRef]
  11. Düzkaya DS, Sahiner NC, Uysal G, Yakut T, Çitak A. Chlorhexidine-impregnated dressings and prevention of catheter-associated bloodstream infections in a pediatric intensive care unit. Crit Care Nurse. 2016;36(6):e1-e7. [CrossRef]
  12. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections [Internet]. National Health Safety Network (NHSN). (cited February 20, 2020) Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf
  13. National Healthcare Safety Network (NHSN) Overview [Internet]. Centers for Disease Control and Prevention (CDC). (January 2014; cited February 20, 2020). Available from: https://www.cdc.gov/nhsn/PDFs/pscManual/validation/pcsManual-2014-valid.pdf
  14. Wright MO, Hebden JN, Allen-Bridson K, Morrell GC, Horan T. Healthcare-associated infections studies project: an American Journal of Infection Control and National Healthcare Safety Network data quality collaboration. Am J Infect Control. 2010;38(5):416-8. [CrossRef]
  15. Ergönül O, Aydin M, Azap A, Başaran S, Tekin S, Kaya S, et al. Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality. J Hosp Infect. 2016;94(4):381-5. [CrossRef]
  16. Longmate AG, Ellis KS, Boyle L, Maher S, Cairns CJ, Lloyd SM, et al. Elimination of central-venous-catheter-related bloodstream infections from the intensive care unit. BMJ Qual Saf. 2011;20(2):174-80. [CrossRef]
  17. Park SW, Ko S, An HS, Bang JH, Chung WY. Implementation of central line-associated bloodstream infection prevention bundles in a surgical intensive care unit using peer tutoring. Antimicrob Resist Infect Control. 2017;6:103. [CrossRef]
  18. Wichmann D, Belmar Campos CE, Ehrhardt S, Kock T, Weber C, Rohde H, et al. Efficacy of introducing a checklist to reduce central venous line associated bloodstream infections in the ICU caring for adult patients. BMC Infect Dis. 2018;18(1):267. [CrossRef]
  19. Lee KH, Cho NH, Jeong SJ, Kim MN, Han SH, Song YG. Effect of central line bundle compliance on central line-associated bloodstream infections. Yonsei Med J. 2018;59(3):376-82. [CrossRef]